Actualización sobre el manejo diagnóstico y terapéutico del feocromocitoma y el paraganglioma

  1. Mateo Gavira, I. 1
  2. Baena Nieto, G. 2
  3. García García-Doncel, L. 2
  4. Torres Barea, I. M. 3
  1. 1 Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Puerta del Mar, Cádiz, España
  2. 2 Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario de Jerez, Jerez de la Frontera, Cádiz, España
  3. 3 Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Punta Europa, Algeciras, Cádiz, España
Erakutsi afiliazioak +
Aldizkaria:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Argitalpen urtea: 2020

Zenbakien izenburua: Enfermedades endocrinológicas y metabólicas (VII)Patología suprarrenal

Saila: 13

Zenbakia: 19

Orrialdeak: 1083-1093

Mota: Artikulua

DOI: 10.1016/J.MED.2020.10.013 DIALNET GOOGLE SCHOLAR

Beste argitalpen batzuk: Medicine: Programa de Formación Médica Continuada Acreditado

Laburpena

Pheochromocytomas and paragangliomas are catecholamine-producing tumours originating from chromaffin cells of the sympathetic nervous system of the adrenal medulla or extra-adrenal chromaffin tissue, respectively. They can be sporadic or be associated with genetic diseases in up to 30% of cases. Biochemical confirmation of the elevation of plasma and/or urinary metanephrines will establish the diagnosis of pheochromocytoma, whereas computed tomography or magnetic resonance imaging is used for the initial location diagnosis. In metastatic pheochromocytoma, 123I-metaiodobenzylguanidine (MIBG) scintigraphy and 18F-FDG or 68Ga-DOTATATE positron emission tomography may be helpful. Surgical resection, the only curative option in these patients, is the treatment of choice for pheochromocytomas and paragangliomas being correct preoperative preparation essential to reduce morbidity and mortality. Malignant pheochromocytoma is a rare entity that can only be diagnosed when metastases are present. There is no effective curative treatment; genetic predisposition, tumor development, disease progression and location of metastases will determine its prognosis.

Erreferentzia bibliografikoak

  • W.F.J. Young Endocrine hypertension H.M. Kronenberg, S. Melmed, K.S. Polonsky, P.R. Larsen (Eds.), Williams textbook of endocrinology (11th ed), Elsevier, Philadelphia (2009), pp. 515-541
  • A.K. Lam Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours Endocr Pathol., 28 (3) (2017), pp. 213-227
  • A.M.A. Berends, E. Buitenwerf, R.R. de Krijger, N.J.G.M. Veeger, A.N.A. van der Horst-Schrivers, T.P. Links, et al. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review Eur J Intern Med., 51 (2018), pp. 68-73
  • M. Omura, J. Saito, K. Yamaguchi, Y. Kakuta, T. Nishikawa Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan Hypertens Res., 27 (3) (2004), pp. 193-202
  • C.Y. Lo , K.Y. Lam, M.S. Wat, Ks. Lam Adrenal pheochromocytoma remains a frequently overlooked diagnosis Am J Surg., 179 (3) (2000), pp. 212-215
  • J.P. Baguet, L. Hammer, T.L. Mazzuco, O. Chabre, J.M. Mallion, N. Sturm, et al. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients Eur J Endocrinol., 150 (5) (2004), pp. 681-686
  • J. Lenders , G. Eisenhofer, M. Mannelli, K. Pacak Phaechromocytoma Lancet, 366 (9486) (2005), pp. 665-675
  • L.M. Gruber , R.P. Hartman, G.B. Thompson, T.J. McKenzie, M.L. Lyden, B.M. Dy, et al. Pheochromocytoma characteristics and behavior differ depending on method of discovery J Clin Endocrinol Metab., 104 (5) (2019), pp. 1386-1393
  • W.F. Young , D.E. Maddox Spells: in search of a cause Mayo Clin Proc., 70 (8) (1995), pp. 757-765
  • T. Noshiro, K. Shimizu, T. Watanabe, H. Akama, S. Shibukawa, W. Miura, et al. Changes in clinical features and long-term prognosis in patients with pheochromocytoma Am J Hypertens., 13 (2000), pp. 35-43
  • J.W. Lenders , Q.Y. Duh, G. Eisenhofer, A.P. Giménez-Roqueplo, S.K. Grebe, M.H. Murad, et al. Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline J Clin Endocrinol Metab, 99 (6) (2014), pp. 1915-1942
  • T. Mune, H. Katakami, Y. Kato, K. Yasuda, S. Matsukura, K. Miura Production and secretion of parathyroid hormone-related protein in pheochromocytoma: participation of an alpha-adrenergic mechanism J Clin Endocrinol Metab., 76 (3) (1993), pp. 757-762
  • J.W. Lenders , K. Pacak, M.M. Walther, W.M. Linehan, M. Mannelli, P. Friberg, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA., 287 (2002), pp. 1427-1434
  • H.P.H. Neumann, W.F. Young Jr., C. Eng Pheochromocytoma and paraganglioma N Engl J Med., 381 (6) (2019), pp. 552-565
  • A. Oleaga , F. Goñi Pheochromocytoma: diagnostic and therapeutic update Endocrinol Nutr., 55 (5) (2008), pp. 202-216
  • E. Grouzmann, L. Drouard-Troalen, E. Baudin, P.F. Plouin, B. Muller, D. Grand, et al. Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma Eur J Endocrinol., 162 (5) (2010), pp. 951-960
  • P.E. Hickman, M. Leong, J. Chang, S.R. Wilson, B. Mc Whinney Plasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of phaeochromocytoma Pathology., 41 (2009), pp. 173-177
  • W.F. Young Jr. K.L. Nieman (Ed.), Clinical presentation and diagnosis of pheochromocytoma (2020) UpToDate. Disponible en: www.UpToDate. com
  • K. Pacak , G. Eisenhofer, H. Ahlman, S.R. Bornstein, A.P. Giménez-Roqueplo, A.B. Grossman, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium Nat Clin Prac End Metab., 3 (2007), pp. 92-102
  • G. Eisenhofer , D. Goldstein, M.M. Walther, P. Friberg, J.W.M. Lenders, H.R. Keiser, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true from false positive test results J Clin Endocrinol Metab., 88 (2003), pp. 2656-2666
  • F. Lumachi , A. Tregnaghi, P. Zuchetta, C. Marzola, M. Cecchin, D. Grasseto, et al. Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: a prospective study Nuc Med Comun., 27 (2006), pp. 583-587
  • J.P. Brito , N. Asi, M.R. Gionfriddo, C. Norman, A.L. Leppin, C. Zeballos-Palacios, et al. The incremental benefit of functional imaging in pheochromocytoma/paraganglioma: a systematic review Endocrine., 50 (1) (2015), pp. 176-186
  • I. Janssen, C.C. Chen, C.M. Millo, A. Ling, D. Taieb, F.I. Lin, et al. PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma Eur J Nucl Med Mol Imaging., 43 (10) (2016), pp. 1784-1791
  • H. Bruynzeel, R.A. Feelders, T.H.N. Groenland, A.H. van den Meiracker, C.H.J. van Eijck, J.F. Lange, et al. Risk factors for hemodynamic instability during surgery for pheochromocytoma J Clin Endocrinol Metab., 95 (2010), pp. 678-685
  • M.A. Nehs , D.T. Ruan Minimally invasive adrenal surgery: an update Curr Opin Endocrinol Diabetes Obes., 18 (2011), p. 193
  • T.N. Weingarten, T.L. Welch, T.L. Moore, G.F. Walters, J.L. Whipple, A. Cavalcante, et al. Preoperative levels of catecholamines and metanephrines and intraoperative hemodynamics of patients undergoing pheochromocytoma and paraganglioma resection Urology., 100 (2017), pp. 131-138
  • B.G. Challis , R.T. Casey, H.L. Simpson, M. Gurnell Is there an optimal preoperative management strategy for phaeochromocytoma/paraganglioma? Clin Endocrinol., 86 (2017), pp. 163-167
  • P.F. Plouin , L. Amar, O.M. Dekkers, M. Fassnacht, A.P. Giménez-Roqueplo, J.W.M. Lenders, et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma Eur J Endocrinol., 174 (2016), pp. G1-G10
  • A. Stenman , J. Zedenius, C.C. Juhlin The value of histological algorithms to predict the malignancy potential of pheochromocytomas and abdominal paragangliomas—a meta-analysis and systematic review of the literature Cancers., 11 (2019), p. 225
  • A. Angelousi, M. Peppa, A. Chrisoulidou, K. Alexandraki, A. Berthon, F. Rueda Faucz, et al. Malignant pheochromocytomas/paragangliomas and ectopic hormonal secretion: a case series and review of the literature Cancers., 11 (5) (2019), p. 72
  • I.Y.F. Mak , A.R. Hayes, B. Khoo, A. Grossman Peptide receptor radionuclide therapy as a novel treatment for metastatic and invasive phaeochromocytoma and paraganglioma Neuroendocrinology., 109 (2019), pp. 287-298
  • S. Hescot, S. Leboulleux, L. Amar, D. Vezzosi, I. Borget, C. Bournaud-Salinas, et al. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma J Clin Endocrinol Metab., 98 (10) (2013), pp. 4006-4012
  • L.T. Van Hulsteiin, N.D. Niemeijer, O.M. Dekkers, E.P. Corssmit 131-MIBG therapy for malignant paraganglioma and phaeocrhomocytoma: systematic review and meta-analysis Clin Endocrinol (Oxf)., 80 (4) (2014), pp. 487-501
  • C. Jiménez , W. Erwin, B. Chasen Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 metaiodobenzylguanidine Cancers., 11 (2019), p. 1018
  • R. Toledo , C. Jiménez Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors F1000Res., 7 (2018), p. F1000
Datuen iturria: Dialnet